Inventiva focuses on oral small-molecule therapies for MASH, a progressive liver disease linked to obesity and type 2 diabetes. Its lead candidate, lanifibranor, is a once-daily pan-PPAR agonist that activates alpha, delta, and gamma receptors. Phase 2b data showed improvements in both inflammation and fibrosis, a profile that some analysts, including those at Jefferies, view as potentially advantageous versus existing treatments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Competition is intensifying. Madrigal Pharmaceuticals already has an approved therapy, and Akero Therapeutics is advancing its own candidate. Inventiva differentiates through its broad mechanism and a fully enrolled Phase 3 trial with just over 1,000 patients in the main cohort. It holds FDA Breakthrough Therapy and Fast Track designations that could speed review if results are positive. The company remains pre-revenue with negative equity and rising debt; it sold its odiparcil asset in late 2025 to concentrate on lanifibranor, which sharpens focus but also concentrates risk in one clinical outcome.
The key near-term event is the NATiV3 Phase 3 readout, guided by management for Q4 2026. The trial is powered above 90% for a composite endpoint of fibrosis improvement of at least one stage plus MASH resolution. Management has indicated that an approximately 18% treatment effect on the primary endpoint would be viewed positively. Positive data could lead to NDA preparation, with a targeted filing in the first half of 2027 and a potential launch around 2028.
A commercial partnership outside Asia remains a frequent topic. Inventiva already has a licensing deal with China’s Chia Tai Tianqing (CTTQ). Jefferies models peak global sales of roughly $4 billion, including about $3 billion outside Asia, assuming such a partner is secured. Analyst ratings show cautious optimism with dispersion: Jefferies keeps a Buy but lowered its target to €6.20 from €7.50 to account for dilution, while seeing potential upside to €8 on positive data. H.C. Wainwright cut its target to $14 from $24, Truist raised its target to $18 from $13, and Stifel reiterates Buy with a $15 target. Overall consensus is Strong Buy, with average targets in the mid-teens but a wide range reflecting binary clinical risk.
The MASH market is expanding amid rising obesity and type 2 diabetes rates. If lanifibranor succeeds, its addressable market could be sizable given the large, under-treated patient population and increasing physician awareness. Macro conditions matter indirectly but importantly for Inventiva. As a cash-burning clinical-stage firm, its financing depends on equity and structured markets. Higher rates and risk aversion raise the cost of capital and dilution risk, while easier conditions support flexibility. The company held roughly €230.9 million in cash, equivalents, and short-term deposits at the end of 2025, supporting a runway to mid-Q1 2027—or mid-Q3 2027 if tranche-three warrants are fully exercised. Regulatory developments at the FDA around MASH endpoints and confirmatory studies could also affect timelines and commercial assumptions.
The central question remains whether lanifibranor can convert its Phase 2b signal into robust Phase 3 results. A positive readout would likely shift focus to regulatory execution, commercialization, partnership economics, and potential acquisition interest. A negative or mixed outcome would pressure the financial runway and strategic options. Longer-term items to monitor include durability of fibrosis improvement in the extension phase, tolerability issues such as weight gain and fluid retention typical of the PPAR class, and the ability to secure a confirmatory study and commercial partner. Cost structure and capital allocation will gain attention if the company moves toward launch readiness. Consensus expectations stay constructive but rest on execution of this single high-stakes catalyst. From what I see, tracking short-term momentum around binary events can add useful context alongside the fundamentals.
Tickeron’s Trend Prediction Engine is an AI-powered tool that helps identify whether a stock may trend bullish, bearish, or sideways over the coming weeks or months. It highlights developing trends, possible breakouts or reversals, and offers historical context across tradable instruments. For event-driven names like Inventiva, it can complement fundamental work by flagging shifts in short-term momentum ahead of major readouts. I’ve used it alongside traditional analysis to stay aware of sentiment changes without replacing core due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
IVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 40 cases where IVA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for IVA crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +7.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVA advanced for three days, in 175 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 126 of 156 cases where IVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
The 10-day RSI Indicator for IVA moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVA as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IVA turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 34 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IVA moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. IVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.215) is normal, around the industry mean (3.596). P/E Ratio (-7.170) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (136.986) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases
Industry Biotechnology